
CLAIMS:

1. A compound of formula **I**, or a pharmaceutically acceptable salt or solvate thereof:



(I)


wherein:

R_1 is hydrogen, C_1-C_6 alkyl, partially or fully deuterated C_1-C_6 alkyl, C_3-C_6 cycloalkyl, C_2-C_6 cyanoalkyl, C_1-C_6 mercaptoalkyl or amino;

R_2 is hydrogen or C_1-C_3 alkyl;

R_3 is hydrogen or oxo;

or **R_2** and **R_3** combine to form a structure of formula **Ia**:



(Ia),

wherein:

X is **CH_2**, **CR_6** or **N**;

 is a double bond when **X** is **CR_6** or **N** and is a single bond when **X** is **CH_2**;


R_4 is hydrogen or C_1-C_3 alkyl;

R_5 is hydrogen or C_1-C_2 alkyl;

or **R_4** and **R_5** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the **CH_2** moiety is optionally substituted with two deuterium atoms;

R_6 is hydrogen;

A is C_5-C_7 cycloalkyl, furanyl, thiophenyl, methylthiophenyl or



,

wherein:

X_1 is hydrogen, halo or methyl;

X_1' is hydrogen or halo;

X_2 is hydrogen, halo or methyl;


X_2' is hydrogen or halo;

X_3 is hydrogen or fluoro;

n is 0 or 1, and when n is 0 a single or double bond joins the carbon atoms to which **R_3** and **R_4** are attached

for use in therapy.

2. A compound of formula **I**, or a pharmaceutically acceptable salt or solvate thereof:



(I),


wherein:

R_1 is hydrogen, C_1-C_6 alkyl, partially or fully deuterated C_1-C_6 alkyl, C_3-C_6 cycloalkyl, C_2-C_6 cyanoalkyl, C_1-C_6 mercaptoalkyl or amino;

R_2 is hydrogen or C_1-C_3 alkyl;

R_3 is hydrogen or oxo;

or **R_2** and **R_3** combine to form a structure of formula **Ia**:



(Ia),

wherein:

X is **CH_2**, **CR_6** or **N**;

------ is a double bond when **X** is **CR_6** or **N** and is a single bond when **X** is **CH_2**;


R_4 is hydrogen or C_1-C_3 alkyl;

R_5 is hydrogen or C_1-C_2 alkyl;

or **R_4** and **R_5** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the CH_2 moiety is optionally substituted with two deuterium atoms;

R_6 is hydrogen;

A is C_5-C_7 cycloalkyl, furanyl, thiophenyl, methylthiophenyl or



,

wherein:

X_1 is hydrogen, halo or methyl;

X_1' is hydrogen or halo;


X_2 is hydrogen, halo or methyl;

X_2' is hydrogen or halo;

X_3 is hydrogen or fluoro;

n is 0 or 1, and when n is 0 a single or double bond joins the carbon atoms to which **R_3** and **R_4** are attached

with the proviso that the following compounds are excluded:



.


3. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein:

R_2 is hydrogen or C_1-C_3 alkyl; and

R_3 is hydrogen or oxo.

4. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein:

R_2 and **R_3** combine to form a structure of formula **Ia**:



(Ia),

wherein:

X is **CH_2**, **CR_6** or **N**;


 is a double bond when **X** is **CR_6** or **N** and is a single bond when **X** is **CH_2**.

5. A compound for use in therapy according to claim 4, or a compound according to claim 4, wherein is a double bond and **X** is **CR_6**.

6. A compound for use in therapy according to claims 1 or 3 to 5, or a compound according to claims 2 to 5, wherein n is 0 and a single bond joins the carbon atoms to which **R_3** and **R_4** are attached.


7. A compound for use in therapy according to claims 1 or 3 to 6, or a compound according to claims 2 to 6, wherein **R_4** and **R_5** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the **CH_2** moiety is optionally substituted with two deuterium atoms.

8. A compound for use in therapy according to claims 1 or 3 to 7, or a compound according to claims 2 to 7, wherein more than 50% of substituents **R_5** and **A** have the stereochemical configuration of formula **Id**




(Id)

9. A compound for use in therapy according to claims 1 or 3 to 7, or a compound according to claims 2 to 7, wherein more than 50% of substituents **R5** and **A** have the stereochemical configuration of formula **Ie**



(Ie)

10. A compound for use in therapy according to claims 1 or 3 to 9, or a compound according to claims 2 to 9, wherein **A** is



,

wherein **X1**, **X1'**, **X2**, **X2'** and **X3** are as defined in claim 1.

11. A compound for use in therapy according to claims 1 or 3 to 10, or a compound according to claims 2 to 10, wherein **R1** is hydrogen, methyl, *d3*-methyl, propyl, cyclopropyl, cyanomethyl, mercaptoethyl or amino.


12. A compound for use in therapy according to claims 3 or 6 to 11, or a compound according to claims 3 or 6 to 11, wherein **R2** is hydrogen or methyl.

13. A compound for use in therapy according to claims 3 or 6 to 12, or a compound according to claims 3 or 6 to 12, wherein **R3** is hydrogen.

14. A compound for use in therapy according to claims 1, 3 to 6 or 8 to 13, or a compound according to claims 2 to 6 or 8 to 13, wherein **R_4** is hydrogen or methyl.

15. A compound for use in therapy according to claims 1, 3 to 6 or 8 to 14, or a compound according to claims 2 to 6 or 8 to 14, wherein **R_5** is hydrogen or methyl.

16. A compound for use in therapy according to claims 1 or 3 to 15, or a compound according to claims 2 to 15, wherein **A** is



,

wherein:

X_1 is hydrogen, fluoro, chloro or methyl;

X_1' is hydrogen, fluoro or chloro;

X_2 is hydrogen, fluoro, chloro, bromo or methyl;

X_2' is hydrogen, fluoro, chloro or bromo;


X_3 is hydrogen or fluoro.

17. A compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of conditions ameliorated by inhibition of dopamine-beta-hydroxylase within the central nervous system.


18. Use of a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treatment of conditions ameliorated by inhibition of dopamine-beta-hydroxylase within the central nervous system.

19. A pharmaceutical composition comprising (i) a therapeutically effective amount of a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof; and (ii) a pharmaceutically acceptable excipient.


20. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is selected from the group consisting of:




,




,




,




,




,



,




, and




or a pharmaceutically acceptable salt or solvate thereof.

21. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

22. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

23. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

24. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

25. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

26. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

27. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is



, or a pharmaceutically acceptable salt or solvate thereof.

28. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is



, or a pharmaceutically acceptable salt or solvate thereof.